<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXTROAMPHETAMINE SULFATEÂ EXTENDED-RELEASE- dextroamphetamine sulfateÂ capsule, extended releaseÂ </strong><br>American Health Packaging<br></p></div>
<h1>
<span class="Bold">DEXTROAMPHETAMINE SULFATE</span><br><span class="Bold">EXTENDED-RELEASE CAPSULES</span><br><br><span class="Bold">CII</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2b13df38-7dde-4307-b7e1-c401ef058310"></a><a name="section-1"></a><p></p>
<h1>8415021/0315<br>Rx only</h1>
<p class="First"><span class="Bold">WARNING</span></p>
</div>
<div class="Warning">
<a name="LINK_d91ef25b-3e99-43b3-acaa-043f3d2d68a2"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE.Â  ADMINISTRATION OF AMPHETAMINES FOR <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">PROLONGED PERIODS</span> OF TIME MAY LEAD TO <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">DRUG DEPENDENCE</span> AND MUST BE AVOIDED.Â  PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.</span><br><br><span class="Bold">MISUSE OF AMPHETAMINES MAY CAUSE <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">SUDDEN DEATH</span> AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_af14e95c-0c14-4e9f-9216-4be4f9ba127b"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dextroamphetamine sulfate is the dextro isomer of the compound <span class="Italics">d,l</span>-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is <span class="Italics">d</span>-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine sulfate extended-release capsules as the neutral sulfate.</p>
<p>Structural formula:</p>
<div class="Figure">
<a name="id1256094617"></a><img alt="Dextroamphetamine structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669a308e-ce09-4ac8-84d9-ee252c5d3223&amp;name=image-01.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_05b08ffd-48ed-455a-a8d1-7035484dddae"></a><a name="section-2.1"></a><p></p>
<h2>Dextroamphetamine Sulfate Extended-Release Capsules</h2>
<p class="First">Each dextroamphetamine sulfate extended-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period.<br><br>Active Ingredient: dextroamphetamine sulfate USP<br><br>Inactive Ingredients: sugar spheres, titanium dioxide, gelatin, shellac glaze-45%, SD-45 alcohol, iron oxide black, propylene glycol, FD&amp;C Blue #2/Indigo Carmine Lake, FD&amp;C Red #40/Allura Red AC Lake, FD&amp;C Blue #1/Brilliant Blue FCF Lake, D&amp;C Yellow #10 Lake, SD3A alcohol, shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, FD&amp;C Blue #2 Aluminum Lake, D&amp;C Red #7 Calcium Lake, hydroxypropyl methylcellulose/hypromellose, macrogol/polyethylene glycol, purified water, ethylcellulose, ammonium hydroxide 28%, medium chain triglycerides, oleic acid</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_8e1cabef-63cc-4322-b9dc-b0d7c879123f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity.Â  Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.<br><br>There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.<br><br>Dextroamphetamine sulfate extended-release capsules are formulated to release the active drug substance in vivo in a more gradual fashion than the standard formulation, as demonstrated by blood levels.Â  The formulation has not been shown superior in effectiveness over the same dosage of the standard, noncontrolled-release formulations given in divided doses.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_f882b647-e81b-46b3-ba02-0390a87002c3"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of the tablet and sustained-release capsule were compared in 12 healthy subjects.Â  The extent of bioavailability of the sustained-release capsule was similar compared to the immediate-release tablet.Â  Following administration of three 5 mg tablets, average maximal dextroamphetamine plasma concentrations (C<span class="Sub">max</span>) of 36.6 ng/mL were achieved at approximately 3 hours.Â  Following administration of one 15 mg sustained-release capsule, maximal dextroamphetamine plasma concentrations were obtained approximately 8 hours after dosing.Â  The average C<span class="Sub">max</span> was 23.5 ng/mL.Â  The average plasma T<span class="Sub">1/2</span> was similar for both the tablet and sustained-release capsule and was approximately 12 hours.<br><br>In 12 healthy subjects, the rate and extent of dextroamphetamine absorption were similar following administration of the sustained-release capsule formulation in the fed (58 to 75 gm fat) and fasted state.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4c8a5c9b-0a4b-490b-bcfa-a78fba685f84"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Dextroamphetamine Sulfate Extended-Release Capsules are indicated in:</p>
<p><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></span><br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">Attention Deficit Disorder</span> with <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span></span>Â <span class="Bold">â€“</span> As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>; DSM-IV) implies the presence of <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.Â  The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home.Â  The symptoms must not be better accounted for by another <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorder</span>.Â  For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful.Â  For the <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactive</span>-Impulsive Type, at least 6 of the followingÂ  symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; â€œon the goâ€?; excessive talking; blurting answers; canâ€™t wait turn; intrusive.Â  The Combined Type requires both inattentive and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span>-impulsive criteria to be met.<br><br><span class="Underline">Special Diagnostic Considerations</span> â€“ Specific etiology of this syndrome is unknown, and there is no single diagnostic test.Â  Adequate diagnosis requires the use of medical and special psychological, educational, and social resources.Â  Learning may or may not be impaired.Â  The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics.<br><br><span class="Underline">Need for Comprehensive Treatment Program</span> â€“ Dextroamphetamine sulfate extended-release capsules are indicated as an integral part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include other measures (psychological, educational, social) for patients with this syndrome.Â  Drug treatment may not be indicated for all patients with this syndrome.Â  Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.Â  Appropriate educational placement is essential and psychosocial intervention is often helpful.Â  When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physicianâ€™s assessment of the chronicity and severity of the patientâ€™s symptoms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_fa6a43ac-becb-4345-88dd-353d0bc18d76"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Advanced <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, symptomatic cardiovascular disease, moderate to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or idiosyncrasy to the sympathomimetic amines, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.<br><br><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitated</span> states.<br><br>Patients with a history of drug abuse.<br><br>During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).<br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_56eca85b-a689-484e-bde2-3c0adca15fc2"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_721eec28-35dd-42fb-bac4-25bd103d37f0"></a><a name="section-6.1"></a><p></p>
<h2>Serious Cardiovascular Events</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_610d73bb-41bb-4230-8304-db86ef80589a"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden Death</span> in Patients with Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems</h2>
<p class="First"><span class="Underline">Children and Adolescents</span> â€“ <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.Â  Although some serious heart problems alone carry an increased risk of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.<br><br><span class="Underline">Adults</span> â€“ <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden deaths</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported in adults taking stimulant drugs at usual doses for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, serious heart rhythm abnormalities, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, or other serious cardiac problems.Â  Adults with such abnormalities should also generally not be treated with stimulant drugs (<span class="Italics">see</span><span class="Bold"><a href="#LINK_fa6a43ac-becb-4345-88dd-353d0bc18d76"> CONTRAINDICATIONS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a6a19b0a-8958-4e3d-9b4f-96cf2d90762e"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and Other Cardiovascular Conditions</h2>
<p class="First">Stimulant medications cause a modest increase in average blood pressure (about 2 to 4 mmHg) and average heart rate (about 3 to 6 bpm), and individuals may have larger increases.Â  While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure.Â  Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> (<span class="Italics">see</span><span class="Bold"><a href="#LINK_fa6a43ac-becb-4345-88dd-353d0bc18d76"> CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_60f39c54-f118-4132-841a-41a54194020b"></a><a name="section-6.4"></a><p></p>
<h2>Assessing Cardiovascular Status in Patients Being Treated with Stimulant Medications</h2>
<p class="First">Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, unexplained <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e10a61e3-81cd-4efe-a033-8c9878d4f148"></a><a name="section-6.5"></a><p></p>
<h2>Psychiatric Adverse Events</h2>
<p class="First"><span class="Underline">Pre-Existing <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span> â€“ Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorder</span>.<br><br><span class="Underline">Bipolar Illness</span> â€“ Particular care should be taken in using stimulants to treat <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in such patients.Â  Prior to initiating treatment with a stimulant, patients with comorbid <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.<br><br><span class="Underline">Emergence of New <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic</span> Symptoms</span> â€“ Treatment emergent <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms, e.g., <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, delusional thinking, or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in children and adolescents without a prior history of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> can be caused by stimulants at usual doses.Â  If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate.Â  In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3,482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span></span> â€“ <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> is often observed in children and adolescents with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>.Â  Although there is no systematic evidence that stimulants cause <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, patients beginning treatment for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> should be monitored for the appearance of, or worsening of, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_24a11067-b5d1-43ed-aba8-d2b1d38c67cc"></a><a name="section-6.6"></a><p></p>
<h2>Long-Term Suppression of Growth</h2>
<p class="First">Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children overÂ 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.Â  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9f8d4e3d-fdf3-44ac-89f9-d6f08a7d35ac"></a><a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, in patients with prior EEG abnormalities in absence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and, very rarely, in patients without a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and no prior EEG evidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.Â  In the presence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fbb2f64e-015b-4b2c-98a4-872eb9a7db15"></a><a name="section-6.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbance</span></h2>
<p class="First">Difficulties with accommodation and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> have been reported with stimulant treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_729a53e8-105e-4577-82cc-4b3789889b31"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">General</span> â€“ The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.<br><br><span class="Bold">Information for Patients</span> â€“ Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.<br><br>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for dextroamphetamine sulfate extended-release capsules. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_4e3a64d6-9e4d-43a7-bcd0-79a4f7749e4b"></a><a name="section-7.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Bold">Acidifying Agents</span> â€“ Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.Â  Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.Â  Both groups of agents lower blood levels and efficacy of amphetamines.<br><br><span class="Bold">Adrenergic Blockers</span> â€“ Adrenergic blockers are inhibited by amphetamines.<br><br><span class="Bold">Alkalinizing Agents</span> â€“ Gastrointestinal alkalinizing agents (sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, etc.) increase absorption of amphetamines.Â  Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.Â  Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.<br><br><span class="Bold">Antidepressants, Tricyclic</span> â€“ Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.<br><br><span class="Bold">MAO Inhibitors</span> â€“ MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.Â  This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and other signs of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.Â  A variety of neurological toxic effects and <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperpyrexia</span> can occur, sometimes with fatal results.<br><br><span class="Bold">Antihistamines</span> â€“ Amphetamines may counteract the sedative effect of antihistamines.<br><br><span class="Bold">Antihypertensives</span>Â â€“ Amphetamines may antagonize the hypotensive effects of antihypertensives.<br><br><span class="Bold">Chlorpromazine</span>Â â€“Â Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.<br><br><span class="Bold">Ethosuximide</span> â€“ Amphetamines may delay intestinal absorption of ethosuximide.<br><br><span class="Bold">Haloperidol</span> â€“ Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.<br><br><span class="Bold">Lithium Carbonate</span> â€“ The stimulatory effects of amphetamines may be inhibited by lithium carbonate.<br><br><span class="Bold">Meperidine</span> â€“ Amphetamines potentiate the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of meperidine.<br><br><span class="Bold">Methenamine Therapy</span> â€“ Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.<br><br><span class="Bold">Norepinephrine</span> â€“ Amphetamines enhance the adrenergic effect of norepinephrine.<br><br><span class="Bold">Phenobarbital</span> â€“ Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.<br><br><span class="Bold">Phenytoin</span> â€“ Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.<br><br><span class="Bold">Propoxyphene</span> â€“ In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> can occur.<br><br><span class="Bold">Veratrum Alkaloids</span> â€“ Amphetamines inhibit the hypotensive effect of veratrum alkaloids.<br><br><span class="Bold">Drug/Laboratory Test Interactions</span><br><br>Amphetamines can cause a significant elevation in plasma corticosteroid levels.Â  This increase is greatest in the evening.<br><br>Amphetamines may interfere with urinary steroid determinations.<br><br><span class="Bold">Carcinogenesis/Mutagenesis</span> â€“ Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of dextroamphetamine sulfate extended-release capsules have not been performed.<br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_ec20e3de-a256-49de-84ab-46e58dc4c274"></a><a name="section-7.2"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects. </span><span class="Italics">Pregnancy Category C</span> â€“ Dextroamphetamine sulfate extended-release capsules have been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose.Â  Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose.Â  While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>, <span class="product-label-link" type="condition" conceptid="25582" conceptname="Tracheoesophageal fistula">tracheoesophageal fistula</span>, and <span class="product-label-link" type="condition" conceptid="4004155" conceptname="Anal atresia">anal atresia</span> (VATER association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy.Â  Dextroamphetamine sulfate extended-release capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br><br><span class="Bold">Nonteratogenic Effects</span> â€“ Infants born to mothers dependent on amphetamines have an increased risk of <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span> and low birth weight.Â  Also, these infants may experience symptoms of withdrawal as demonstrated by <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, including <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and significant <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>.<br><br><span class="Bold">Nursing Mothers</span> â€“ Amphetamines are excreted in human milk.Â  Mothers taking amphetamines should be advised to refrain from nursing.<br><br><span class="Bold">Pediatric Use</span> â€“ Long-term effects of amphetamines in pediatric patients have not been well established.<br><br>Dextroamphetamine sulfate extended-release capsules are not recommended for use in pediatric patients younger than 6 years of age with <span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">Attention Deficit Disorder</span> with <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> described under <span class="Bold"><a href="#LINK_4c8a5c9b-0a4b-490b-bcfa-a78fba685f84">INDICATIONS AND USAGE</a></span>. Â <br><br>Clinical experience suggests that in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.<br><br>Amphetamines have been reported to exacerbate motor and phonic <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> and Touretteâ€™s syndrome.Â  Therefore, clinical evaluation for <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> and Touretteâ€™s syndrome in children and their families should precede use of stimulant medications.<br><br>Data are inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore, growth should be monitored during treatment. <br><br>Drug treatment is not indicated in all cases of <span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">Attention Deficit Disorder</span> with <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> and should be considered only in light of the complete history and evaluation of the child.Â  The decision to prescribe amphetamines should depend on the physicianâ€™s assessment of the chronicity and severity of the childâ€™s symptoms and their appropriateness for his or her age.Â  Prescription should not depend solely on the presence of one or more of the behavioral characteristics.<br><br>When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_76b5702a-e397-478d-8ee5-a5eeaa399c24"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Cardiovascular</span> â€“ <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevation of blood pressure.Â  There have been isolated reports of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> associated with chronic amphetamine use.<br><br><span class="Bold">Central Nervous System</span> â€“ <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic episodes</span> at recommended doses (rare), overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, exacerbation of motor and phonic <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> and Touretteâ€™s syndrome.<br><br><span class="Bold">Gastrointestinal</span> â€“ Dryness of the mouth, unpleasant taste, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, other <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.Â  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> may occur as undesirable effects.<br><br><span class="Bold">Allergic</span> â€“ <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>.<br><br><span class="Bold">Endocrine â€“ </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, changes in libido.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_ba8bb038-75d0-4fe8-aeb8-f897f02e1a66"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Dextroamphetamine sulfate is a Schedule II controlled substance.<br><br>Amphetamines have been extensively abused.Â  Tolerance, extreme psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and severe social <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> have occurred.Â  There are reports of patients who have increased the dosage to many times that recommended.Â  Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG.<br><br>Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with amphetamines include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>.Â  The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.Â  This is rare with oral amphetamines.<br></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_07809a41-4542-4bc0-899e-a477d654097b"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Individual patient response to amphetamines varies widely.Â  While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal.<br><br>In rats, the oral LD<span class="Sub">50</span> of dextroamphetamine sulfate is 96.8 mg/kg.<br><br>Manifestations of acute overdosage with amphetamines include <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, rapid respiration, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, assaultiveness, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, panic states.<br><br><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation.<br><br>Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>.Â  Fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is usually preceded by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.<br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5d051bcf-084b-4a39-ba82-7ef545d4b351"></a><a name="section-10.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Consult with a Certified Poison Control Center for up-to-date guidance and advice.Â  Management of acute amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic, and sedation.Â  Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard.Â  Acidification of the urine increases amphetamine excretion, but is believed to increase risk of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> if <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> is present.Â  If acute, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> complicates amphetamine overdosage, administration of intravenous phentolamine (Bedford Laboratories) has been suggested.Â  However, a gradual <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> will usually result when sufficient sedation has been achieved.<br><br>Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.<br><br>Since much of the dextroamphetamine sulfate extended-release capsule medication is coated for gradual release, therapy directed at reversing the effects of the ingested drug and at supporting the patient should be continued for as long as overdosage symptoms remain. Saline cathartics are useful for hastening the evacuation of pellets that have not already released medication.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_c267aca1-4afc-4de7-94bb-e3ac8279c8b0"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted.Â  Late evening doses should be avoided because of the resulting <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span></span> â€“ Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response.<br><br><span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">Narcolepsy</span> seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate extended-release capsules may be used.Â  The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained.Â  In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained.Â  If bothersome adverse reactions appear (e.g., <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>), dosage should be reduced. Dextroamphetamine sulfate extended-release capsules may be used for once-a-day dosage wherever appropriate. <br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">Attention Deficit Disorder</span> with <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span></span> â€“ The dextroamphetamine sulfate extended-release capsule formulation is not recommended for pediatric patients younger than 6 years of age.<br><br><span class="Bold">In pediatric patients 6 years of age and older,</span> start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained.Â  Only in rare cases will it be necessary to exceed a total of 40 mg per day.<br><br>Dextroamphetamine sulfate extended-release capsules may be used for once-a-day dosage wherever appropriate.<br><br>Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_42f8b477-c145-49cb-8491-b46014a2240c"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Dextroamphetamine Sulfate Extended-Release Capsules</span> â€“ Each capsule, with white opaque cap and white opaque body, contains dextroamphetamine sulfate.Â  The 15 mg capsule is imprinted with an <a name="id1111"></a><img alt="brand mark" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669a308e-ce09-4ac8-84d9-ee252c5d3223&amp;name=dextroamphetamine-sulfate-extended-release-4.jpg"><span class="Sup">Â®</span> on the cap and is imprinted 8962 15 mg on the body in pink.</p>
<p>Unit dose packages of 30 (3 x 10) NDC 60687-150-21</p>
<p><br>Store at 20Âº to 25ÂºC (68Âº to 77ÂºF) [see USP Controlled Room Temperature]. Â </p>
<p><a name="id1123"></a><img alt="brand mark" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669a308e-ce09-4ac8-84d9-ee252c5d3223&amp;name=dextroamphetamine-sulfate-extended-release-5.jpg"> is a trademark of Mallinckrodt Inc.</p>
<p><span class="Bold">DEA Order Form Required.</span></p>
<p><span class="Bold">PACKAGING INFORMATION</span></p>
<p>American Health Packaging unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (see <a href="#LINK_42f8b477-c145-49cb-8491-b46014a2240c">How Supplied</a> section) contain drug product from MALLINCKRODT INC as follows:<br>(15 mg / 30 UD) NDC 60687-150-21 packaged from NDC 0406-8962</p>
<p>Packaged and Distributed by:<span class="Bold"><br>American Health Packaging<br></span>Columbus, OH 43217</p>
<p>8415021/0315</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_d564e02e-1bc4-4c75-81ca-b90b889b69f0"></a><a name="section-13"></a><p></p>
<h1>8415021/0315<br>MEDICATION GUIDE<br>Dextroamphetamine Sulfate Extended-Release Capsules<br>CII</h1>
<p class="First">Read the Medication Guide that comes with dextroamphetamine sulfate extended-release capsulesÂ  before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your or your childâ€™s treatment with dextroamphetamine sulfate extended-release capsules.</p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">What is the most important information I should know about Dextroamphetamine Sulfate Extended-Release Capsules? </span><br><br><span class="Bold">The following have been reported with use of dextroamphetamine sulfate extended-release capsules and other stimulant medicines. </span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold"><span class="Underline">Heart-related problems</span>:</span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients who have heart problems or heart defects </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in adults </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and heart rate</span></dd>
</dl>
<p>Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. <br><br>Your doctor should check you or your child carefully for heart problems before starting dextroamphetamine sulfate extended-release capsules.<br><br>Your doctor should check your or your childâ€™s blood pressure and heart rate regularly during treatment with dextroamphetamine sulfate extended-release capsules. <br><br><span class="Bold">Call your doctor right away if you or your child has any signs of heart problems such as <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> while taking dextroamphetamine sulfate extended-release capsules.</span><br></p>
<dl>
<dt>2.</dt>
<dd><span class="Bold"><span class="Underline">Mental (Psychiatric) problems:</span></span></dd>
<dt>Â </dt>
<dd><span class="Bold"><br>All Patients </span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">new or worse behavior and thought problems </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">new or worse bipolar illness </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">new or worse <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> </span></dd>
<dt>Â </dt>
<dd><span class="Bold"><br>Children and Teenagers</span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">new <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms (such as hearing voices, believing things that are not true, are suspicious) or new <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms </span></dd>
</dl>
<p>Tell your doctor about any mental problems you or your child have, or about a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar illness, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. <br><br><span class="Bold">Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking dextroamphetamine sulfate extended-release capsules, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.</span></p>
</td></tr></tbody>
</table>
<p><span class="Bold">What are Dextroamphetamine Sulfate Extended-Release Capsules?</span><br><br>Dextroamphetamine sulfate extended-release capsules are a central nervous system stimulant prescription medicine.<span class="Bold"> It is used for the treatment of Attention-Deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> Disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>).</span><br><br>Dextroamphetamine sulfate extended-release capsules may help increase attention and decrease impulsiveness and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in patients with <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>. <br><br>Dextroamphetamine sulfate extended-release capsules should be used as a part of a total treatment program for <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> that may include counseling or other therapies. <br><br>Dextroamphetamine sulfate extended-release capsules are also used in the treatment of a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span> called <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.</p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Dextroamphetamine sulfate extended-release capsules are a federally controlled substance (CII) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep dextroamphetamine sulfate extended-release capsules in a safe place to prevent misuse and abuse. Selling or giving away dextroamphetamine sulfate extended-release capsules may harm others, and is against the law</span>.</p>
<p>Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.</p>
</td></tr></tbody>
</table>
<p><span class="Bold">Who should not take Dextroamphetamine Sulfate Extended-Release Capsules?</span><br><br><span class="Bold">Dextroamphetamine sulfate extended-release capsules should not be taken if you or your child: </span></p>
<dl>
<dt>â€¢</dt>
<dd>have heart disease or hardening of the arteries</dd>
<dt>â€¢</dt>
<dd>have moderate to severe high blood pressure</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span></dd>
<dt>â€¢</dt>
<dd>have an eye problem called <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></dd>
<dt>â€¢</dt>
<dd>are very anxious, <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span>, or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span></dd>
<dt>â€¢</dt>
<dd>have a history of drug abuse</dd>
<dt>â€¢</dt>
<dd>are taking or have taken within the past 14 days an anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicine called a monoamine oxidase inhibitor or MAOI</dd>
<dt>â€¢</dt>
<dd>is sensitive to, allergic to, or had a reaction to other stimulant medicines</dd>
</dl>
<p>Dextroamphetamine sulfate extended-release capsules are not recommended for use in children younger than 6 years old.<br><br><span class="Bold">Dextroamphetamine sulfate extended-release capsules may not be right for you or your child. Before starting dextroamphetamine sulfate extended-release capsules tell your or your childâ€™s doctor about all health conditions (or a family history of) including: </span></p>
<dl>
<dt>â€¢</dt>
<dd>heart problems, heart defects, high blood pressure</dd>
<dt>â€¢</dt>
<dd>mental problems including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, bipolar illness, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span> or Touretteâ€™s syndrome</dd>
<dt>â€¢</dt>
<dd>thyroid problems</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or have had an abnormal brain wave test (EEG)</dd>
</dl>
<p>Tell your doctor if you or your child is pregnant, planning to become pregnant, or breastfeeding.</p>
<p><span class="Bold">Can Dextroamphetamine Sulfate Extended-Release Capsules be taken with other medicines?</span><br><br><span class="Bold">Tell your doctor about all of the medicines that you or your child take including prescription and nonprescription medicines, vitamins, and herbal supplements. </span>Dextroamphetamine sulfate extended-release capsules and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking dextroamphetamine sulfate extended-release capsules.</p>
<p>Your doctor will decide whether dextroamphetamine sulfate extended-release capsules can be taken with other medicines.</p>
<p><span class="Bold">Especially tell your doctor if you or your child takes: </span></p>
<dl>
<dt>â€¢</dt>
<dd>anti-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> medicines including MAOIs</dd>
<dt>â€¢</dt>
<dd>blood pressure medicines</dd>
<dt>â€¢</dt>
<dd>antacids</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines</dd>
</dl>
<p>Know the medicines that you or your child takes. Keep a list of your medicines with you to show your doctor and pharmacist.</p>
<p><span class="Bold">Do not start any new medicine while taking dextroamphetamine sulfate extended-release capsules without talking to your doctor first.</span></p>
<p><span class="Bold">How should Dextroamphetamine Sulfate Extended-Release Capsules be taken?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Take dextroamphetamine sulfate extended-release capsules exactly as prescribed.</span> Your doctor may adjust the dose until it is right for you or your child. </dd>
<dt>â€¢</dt>
<dd>Dextroamphetamine sulfate extended-release capsules are usually taken once a day in the morning. Dextroamphetamine sulfate extended-release capsules are an extended release capsule. It releases medicine into your body throughout the day. </dd>
<dt>â€¢</dt>
<dd>From time to time, your doctor may stop treatment with dextroamphetamine sulfate extended-release capsules for a while to check <span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span> symptoms. </dd>
<dt>â€¢</dt>
<dd>Your doctor may do regular checks of the blood, heart, and blood pressure while taking dextroamphetamine sulfate extended-release capsules. Children should have their height and weight checked often while taking dextroamphetamine sulfate extended-release capsules. Treatment with dextroamphetamine sulfate extended-release capsules may be stopped if a problem is found during these check-ups. </dd>
<dt>â€¢</dt>
<dd><span class="Bold">If you or your child takes too much dextroamphetamine sulfate extended-release capsules or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, call your doctor or poison control center right away, or get emergency treatment.</span></dd>
</dl>
<p><span class="Bold">What are possible side effects of Dextroamphetamine Sulfate Extended-Release Capsules?</span><br><br>See <span class="Bold">â€œWhat is the most important information I should know about Dextroamphetamine Sulfate Extended-Release Capsules?â€?</span> for information on reported heart and mental problems. <br><br><span class="Bold">Other serious side effects include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>slowing of growth (height and weight) in children </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, mainly in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </dd>
<dt>â€¢</dt>
<dd>eyesight changes or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> </dd>
</dl>
<p><span class="Bold">Common side effects include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>fast heartbeat</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span></dd>
<dt>â€¢</dt>
<dd>trouble sleeping</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></dd>
</dl>
<p>Dextroamphetamine sulfate extended-release capsules may affect your or your childâ€™s ability to drive or do other dangerous activities.<br><br>Talk to your doctor if you or your child has side effects that are bothersome or do not go away.<br><br>This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.<br><br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br><br><span class="Bold">How should I store Dextroamphetamine Sulfate Extended-Release Capsules?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store dextroamphetamine sulfate extended-release capsules in a safe place at room temperature, 68Âº to 77ÂºF (20Âº to 25ÂºC). Protect from light.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Keep dextroamphetamine sulfate extended-release capsules and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General information about Dextroamphetamine Sulfate Extended-Release Capsules</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use dextroamphetamine sulfate extended-release capsules for a condition for which it was not prescribed. Do not give dextroamphetamine sulfate extended-release capsules to other people, even if they have the same condition. It may harm them and it is against the law.<br><br>This Medication Guide summarizes the most important information about dextroamphetamine sulfate extended-release capsules. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about dextroamphetamine sulfate extended-release capsules that was written for healthcare professionals, or you can visit www.Mallinckrodt.com or call 1-800-778-7898.</p>
<p><span class="Bold">What are the ingredients in Dextroamphetamine Sulfate Extended-Release Capsules?</span><br><br><span class="Bold">Active Ingredient: </span>dextroamphetamine sulfate USP</p>
<p><span class="Bold">Inactive Ingredients: </span>sugar spheres, titanium dioxide, gelatin, shellac glaze-45%, SD-45 alcohol, iron oxide black, propylene glycol, FD&amp;C Blue #2/Indigo Carmine Lake, FD&amp;C Red #40/Allura Red AC Lake, FD&amp;C Blue #1/Brilliant Blue FCF Lake, D&amp;C Yellow #10 Lake, SD3A alcohol, shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, strong <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> solution, FD&amp;C Blue #2 Aluminum Lake, D&amp;C Red #7 Calcium Lake, hydroxypropyl methylcellulose/hypromellose, macrogol/polyethylene glycol, purified water, ethylcellulose, ammonium hydroxide 28%, medium chain triglycerides, oleic acid</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Packaged and Distributed by:<span class="Bold"><br>American Health Packaging<br></span>Columbus, OH 43217</p>
<p>8415021/0315</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_f1159330-846b-4a74-a617-fd3d0ae782cc"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1085113877"></a><img alt="Dextroamphetamine Sulfate ER Capsules 15 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669a308e-ce09-4ac8-84d9-ee252c5d3223&amp;name=image-02.jpg">
</div>
<p class="First"><span class="Bold">NDC 60687-150-21</span></p>
<p><span class="Bold">DEXTROAMPHETAMINE<br>SULFATE</span><br>EXTENDED-RELEASE<br>CAPSULES</p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">15 mg</span></p>
<p><span class="Bold">30 Capsules (3 x 10)</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense with the accompanying<br>Medication Guide to each patient.</p>
<p><span class="Bold">Each Capsule Contains:</span><br>Dextroamphetamine Sulfate USPâ€¦â€¦â€¦â€¦â€¦â€¦..15 mg<br>Each extended-release capsule contains<br>dextroamphetamine sulfate, 15 mg, so prepared that an initial<br>dose is released promptly and the remaining medication is<br>released gradually over a prolonged period. </p>
<p><span class="Bold">Usual Dosage:</span> See package insert for full prescribing<br>information. </p>
<p><span class="Bold">Store</span> at 20Âº to 25ÂºC (68Âº to 77ÂºF); excursions permitted<br>between 15Âº to 30ÂºC (59Âº to 86ÂºF) [see USP Controlled Room<br>Temperture].</p>
<p><span class="Bold">DEA Order Form Required. </span></p>
<p><span class="Bold">Keep this and all drugs out of reach of children. </span></p>
<p><span class="Bold">Rx Only</span></p>
<p>The drug product contained in this package is from<br>NDC # 0406-8962, Mallinckrodt Inc. </p>
<p>Packaged and Distributed by:<br>American Health Packaging<br>Columbus, Ohio 43217</p>
<p>715021<br>Rev. 03/2015</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXTROAMPHETAMINE SULFATEÂ 		
					EXTENDED-RELEASE</strong><br><span class="contentTableReg">dextroamphetamine sulfate capsule, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60687-150(NDC:0406-8962)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXTROAMPHETAMINE SULFATE</strong> (DEXTROAMPHETAMINE) </td>
<td class="formItem">DEXTROAMPHETAMINE SULFATE</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MEDIUM-CHAIN TRIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>OLEIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 7</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;8962;15;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60687-150-21</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60687-150-11</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076353</td>
<td class="formItem">06/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>American Health Packaging
							(929561009)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">American Health Packaging</td>
<td class="formItem"></td>
<td class="formItem">929561009</td>
<td class="formItem">REPACK(60687-150)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>669a308e-ce09-4ac8-84d9-ee252c5d3223</div>
<div>Set id: 669a308e-ce09-4ac8-84d9-ee252c5d3223</div>
<div>Version: 1</div>
<div>Effective Time: 20150602</div>
</div>
</div>Â <div class="DistributorName">American Health Packaging</div></p>
</body></html>
